DBDorothy R. Barnard

Dorothy R. Barnard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dorothy R. Barnard has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Todd A. Alonzo

    Children's Oncology Group, Arcadia, California

    2 shared publications
  • William G. Woods

    Children's Health Care of Atlanta, Emory University, Atlanta, Georgia

    2 shared publications
  • Beverley Lange

    From Dalhousie University, Halifax, NS; Children's Hospital of Philadelphia, PA; Keck School of Medicine, University of Southern California, Los Angeles; Roger Maris Cancer Center, Fargo, ND; University of North Carolina, Chapel Hill; Children's Hospital Orange County, Orange, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Children's Oncology Group, Arcadia, CA; and Emory University, Atlanta, GA

    1 shared publication
  • Beverly Lange

    1 shared publication
  • Cindy Wakefield

    1 shared publication
  • David Feeny

    1 shared publication

Latest Publications

  • Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group

    by Dorothy R. Barnard, Todd A. Alonzo, Robert B. Gerbing, Beverly Lange, William G. Woods

    Background: Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features.Procedure: Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0–M5. All children were entered on the Children's Cancer Group therapeutic research study CCG 2891.Results: The presentation and outcomes of the 132 children diagnosed with MDS (60 children), AML FAB M6 (19 children), or AML FAB M7 (53 children) were similar. Children with AML FAB M7 were diagnosed at a significantly younger age (P = 0.001). Children with MDS, M6, or M7 had significantly lower white blood cell (WBC) counts (P = 0.001), lower peripheral blast counts (P < 0.001), and an increased frequency of −7/7q‐ (P = 0.003) at presentation. All three groups had significantly inferior overall survival (OS) (P < 0.001) and event free survival (P < 0.001) compared with the 748 children diagnosed with AML FAB M0–M5 when assessed from entry on study. This poor survival was largely attributable to induction death and failure. However, when assessed from successful completion of induction therapy, the 5‐year OS (P = 0.090)(49.1 vs. 56.9%) and disease‐free survival (DFS) (P = 0.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with AML.Conclusions: Childhood AML FAB M6 and AML M7 resemble MDS in presentation, poor induction success rates, and outcomes. Pediatr Blood Cancer 2007;49:17–22.


  • Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer – An update

    by D R Barnard, Wg Woods

    Treatment-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/t-AML) is a devastating complication of treatment for childhood cancer. However, the major cause of premature death of children treated for cancer remains their primary cancer. The understanding of the presentation, incidence, predisposing risk factors and pathobiology of t-MDS/t-AML is increasing. This increased understanding has not yet been translated into improved outcomes of therapy for t-MDS/t-AML. However, newer approaches are under study.


  • Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents

    by Dorothy Barnard, Michael Woloski, David Feeny, Patricia McCusker, John Wu, Michele David, James Bussel, Jean Lusher, Cindy Wakefield, Susan Henriques, et al.

    Immune thrombopenic purpura (ITP) is an important childhood hematologic disorder that is often frightening to patients and their parents because of its acute onset and bleeding symptoms. There is no consensus on the management of ITP in children. Pediatric hematologists have differing management philosophies, yet most, explicitly or implicitly, incorporate into their management approach the potential impact on the child's and family's quality of life. There is no validated ITP-specific health-related quality-of-life instrument for use with children with ITP, nor is there one to evaluate the burden experienced by their parents. ITP is usually a self-limited disorder. With current controversy over management approaches, an evaluation of the disease burden experienced by the child and the family may assist with the assessment of alternative treatment approaches. Using standard clinimetric methodology, 88 children with acute or chronic ITP, along with their parents, participated in the development of the instruments. The 26-item ITP-Child Quality-of-Life Questionnaire includes five domains: treatment side effect-related, intervention-related, disease-related, activity-related, and family-related. This instrument can be used as a self-completed instrument for most children older than 7 years or as a proxy-completed instrument by parents of children younger than 7 years. The 26-item ITP-Parental Burden Quality-of-Life Questionnaire includes six domains: concerns related to diagnosis/investigation, treatment/disease monitoring, monitoring of child's activities, interference with daily life, disease outcome, and emotional impacts. The first steps of the development of these formally developed instruments are complete. The instruments are available for study to validate and test their responsiveness through use in clinical research studies. Such instruments are increasingly recognized as important for comprehensive measurement of patient outcomes in this and other areas of pediatric hematology/oncology practice.


  • Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation

    by Dorothy R. Barnard, Beverley Lange, Todd A. Alonzo, Jonathan Buckley, J. Nathan Kobrinsky, Stuart Gold, Steven Neudorf, Jean Sanders, Laura Burden, William G. Woods

    There has not been a reported series of children with therapy-induced myelodysplastic syndrome/acute myeloid leukemia (tMDS/tAML) who were treated systematically. This paper describes 24 children with tMDS/tAML who were assigned randomly to standard- or intensive-timing induction on protocol CCG 2891. Presenting features and outcomes of those children were compared with those of 960 patients with de novo MDS (62 patients) or AML (898 patients). Children with tMDS/tAML were older at presentation (P = .015), had lower white blood cell counts (P = .01), and were more likely to have MDS (21% vs 7%) (P = .02) and trisomy 8 (P = .06). Fewer had hepatomegaly (P = .02), splenomegaly (P = .03), hepatosplenomegaly (P = .02), or classic AML translocations [t(8;21), t(15;17), 16q22; P = .02]. They had a poorer induction rate (50% vs 72%,P = .016), overall survival (26% vs 47% at 3 years,P = .007), and event-free survival (21% vs 39% at 3 years, P =.023). Disease-free survival after achieving remission was similar (45% vs 53%, P = .868). Children with tMDS/tAML who received intensive-timing induction had better outcomes than those who received standard-timing induction (overall survival 32% vs 0%, P = .54). In this study, the latency period to development of tMDS/tAML was the same for presumed alkylator-induced as for topoisomerase-induced myeloid leukemia. The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standard-timing induction appears less effective for this population.